Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
251. |
ECCT/20/06/03 | CVIA078 A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine |
Principal Investigator(s) 1. Nathanial Kelsey Copeland Site(s) in Kenya Kombewa Clinical Research Centre |
View |
252. |
ECCT/20/06/02 | EMPACTA Covid19 Study A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya AgaKhan University Hospital Nairobi |
View |
253. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
View |
254. |
ECCT/20/05/03 | A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment |
Principal Investigator(s) 1. Victor Mudhune Site(s) in Kenya Kisumu Clinical Research Center |
View |
255. |
ECCT/20/05/02 | COPCOV Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) |
Principal Investigator(s) 1. Anthony Oliwa Etyang Site(s) in Kenya 1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) 2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county) |
View |